Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Shift from visceral to subcutaneous adipose tissue in Cyp17a1-knockout rats prevents the progression of metabolic syndrome.

Jeon BJ., Lee JH., Kwon DH., Kim HK., Jang G.

Animal Study on Type 2 Diabetes, published in PLoS One (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
PLoS One (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41385510
PMCID
PMC12700391
DOI
10.1371/journal.pone.0311478

Abstract (original English)

In this study, we investigated the effects of Cyp17a1 gene knockout (KO) on obesity and metabolic syndrome. Cyp17a1 KO in rats using CRISPR-Cas9 resulted in sex dimorphism and obesity, and interestingly, site-specific accumulation was found in subcutaneous adipose tissue (SAT). Surprisingly, an insulin tolerance test and oral glucose tolerance test did not show any issues with insulin sensitivity and secretion despite hyperglycemia. In addition, Cyp17a1 KO rats showed normal plasma insulin and free fatty acid levels compared to wild-type rats, and blood biochemistry analysis revealed normal triglyceride, total cholesterol, high-density lipoprotein, and low-density lipoprotein levels. Cyp17a1 KO adipose-tissue-derived stem cells from SAT showed increased expression of KLF5, an early adipogenesis marker, which implies enhanced adipogenic potential in SAT. When gene expression associated with lipid, glucose, and insulin metabolism as well as inflammation in adipose tissue was examined, a metabolic shift to SAT was discovered in the Cyp17a1 KO group. In conclusion, in the Cyp17a1 KO rat models we generated for the first time, the phenotype promoted by obesity reflected metabolically healthy obesity hypothesis, but this did not exhibit metabolic syndrome-like features due to enhanced metabolism in the SAT.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMetabolic SyndromeRatsSubcutaneous FatMaleIntra-Abdominal FatSteroid 17-alpha-HydroxylaseFemaleGene Knockout TechniquesObesity

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research